Companies Merge to Form NeXstar

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to form NeXstar Pharmaceuticals, Inc. One focus of the new company will be the liposomal delivery of oligonucleotides. The company's initial product, AmBisome, is a liposomal formulation of amphotericin B, which has been approved for marketing in 16 countries for the treatment of life-threatening systemic fungal infections that fail to respond to conventional amphotericin B therapy.

BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to formNeXstar Pharmaceuticals, Inc. One focus of the new company willbe the liposomal delivery of oligonucleotides. The company's initialproduct, AmBisome, is a liposomal formulation of amphotericinB, which has been approved for marketing in 16 countries for thetreatment of life-threatening systemic fungal infections thatfail to respond to conventional amphotericin B therapy.

A phase III trial of the product in conjunction with the NationalCancer Institute has recently been announced.

Articles in this issue
Genetic Therapy Gets NIH Patent
Fusion Product Delivers Potent Toxin to Malignant Cells
Retinoic Acid May Enhance Chemo In Ovarian Ca Cells
Compounds Block ras Gene Function Compounds Block ras Gene Function
Companies Merge to Form NeXstar
Scientists Debate Best Way to Spur Immune System to Battle Cancer: Interleukins or Altered Tumor Cells?
Antiangiogenesis Tested in Pediatric Tumors
Delivery of Effective Cyclophosphamide Metabolite Could Reduce Toxicity
New Director Attends Office of Alternative Medicine Advisory Meeting
Cancer Vaccine Made From Purified Tumor Antigen Enters Phase III Melanoma Trials
Worksite Cancer Screening Boosts Employee Morale
Centocor CA 125 II, New Version of CA 125 Assay, Is Now Available
Women Smokers Have High Nicotine Concentrations in Their Cervical Mucus
Ocean Organisms a Source of New Anticancer Drugs
House Wants to Cut NIH Budget
Recent Videos
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Related Content
Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Talquetamab Bridging Strategy Appears Feasible in R/R Multiple Myeloma

Russ Conroy
August 20th 2025
Article

Bridging therapy with talquetamab achieved “notable” disease control among patients with multiple myeloma in a retrospective study.

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Emotional Distress May Confer Worse Immunotherapy Outcomes in NSCLC

Russ Conroy
August 19th 2025
Article

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Roman Fabbricatore
August 19th 2025
Article

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.

Carfilzomib Regimens Improve MRD Outcomes in Older, Fit NDMM Population

Russ Conroy
August 19th 2025
Article

Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.